Sheet

PTO/SB/08A (09-06)
Approved for use through 03/31/2007. OMB 0851-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

m 1449/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Complete if Known				
Application Number	10/580,011			
Filing Date				
First Named Inventor	Tim Fat Tam			
Art Unit				
Examiner Name				
Attorney Docket Number	PT2116001			

Examiner Initials*	Cite No.1	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant	
		Number-Kind Code ^{2 (Filmown)}			Figures Appear	
191		^{US-} RE 35,948	11-03-1998	Hider et al.		
		^{US-} 5,480,894	01-02-1996	Hider et al.		
		^{US-} 5,688,815	11-18-1997	Zbinden, Paul		
1		^{US-} 6,426,418	07-30-2002	Tam, T. F. and Li, W.		
1		^{US-} 6,335,353	01-01-2002	Hider et al.		
N/II		^{US-} 6,448,273	12-03-2002	Sawdon et al.		
P		US-				
t		US-			,	
		US-				
		US-		·		
		US-				
		US-				
		US-				
		US-				
		US-				
		US-		·		
		US-				
		US-				
		US-				

	 FORE	IGN PATENT DOCL			_
Examiner Cite Initials* No.1	Foreign Patent Document	Publication Date	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages	١
0	Country Code ³ "Number ⁴ "Kind Code ⁸ (If known)	MM-DD-YYYY		Or Relevant Figures Appear	ppear T
1/04	CA 2,379,370	09-28-2003	Apotex Inc.		
7					L
					l
					Ļ
					L
				1	ı

Examiner		Date	
Signature		Considered	
Orginature .	,		

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered, include copy of this form with next communication to applicant. Applicant's unique citation designation number (optional). See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. Mind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

PTO/SB/08B (09-06)
Approved for use through 03/31/2007. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Substitute for form 1449/PTO		Complete if Known
Gastana ia	Application Number	10/580,011
INFORMATION DISCLOSU	RE Filing Date	
STATEMENT BY APPLICAL	NT First Named Inventor	Tim Fat Tam
	Art Unit	
(Use as many sheets as necessary)	Examiner Name	
Sheet 2 of 3	Attorney Docket Number	PT2116001

<u>-</u>		NON PATENT LITERATURE DOCUMENTS	
Examiner Initials*			T²
Br		BARTFAY et al., Cardiac function and cytotoxic aldehyde production in a murine model of chronic iron-overload, Cardiovascular Research, 1999, 43(4), pp. 892-900	
		BERGERON et al., A Comparison of the Iron-Clearing Properties of 1,2-Dimethyl-3-Hydroxypyrid-4-One, Blood, 1992, Vol. 79, No. 7, pp. 1882-1890	
		Crumbliss, A.L., Iron Chelation in Biology (http://www.medicine.uiowa.edu/FRRB/VirtualSchool/Crumbliss-Fe.pdf)	
		DHUNGANA et al., Fe(III) Coordination Properties of a New Saccharide-Based Exocyclic Trihydroxamate Analogue, Inorganic Chemistry, January 13, 2003, 42(1), pp. 42-50	
		HENDRICKSON et al, The Consequences of Chemical Bonding: Classes of Molecules, Organic Chemistry, Third Edition, 1970, McGraw Hill, p. 72	
		HERSHKO et al., The iron-loaded gerbil model revisited: Effects of deferoxamine and deferiprone treatment, J. Lab. Clin. Med., 2002, Vol. 139, No. 1, pp. 50-58	
		KING, R.E., Tablets, Capsules, and Pills, Remington's Pharmaceutical Sciences, 15th Edition, 1975, Mack Publishing Company, Easton, PA, ch. 89, pp. 1576-1607	
		KONTOGHIORGHES, G.J., Orally active a-Ketohydroxypyridine Iron Chelators: Studies in Mice, Molecular Pharmacology, 1986, 30(6), pp. 670-673	
		PERNAROWSKI, M., Solutions, Emulsions, and Suspensions, Remington's Pharmaceutical Sciences, 15th Edition, 1975, Mack Publishing Company, Easton, PA, ch. 83, pp. 1436-1460	
Mar	-	PIERRE, J. L. and FONTECAVE, M., Iron and activated oxygen species in biology: The basic chemistry, BioMetals, 1999, 12, pp. 195-199	

Examiner	Date	
Signature	Considered	

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

considered. Include copy of this form with next communication to applicams.

Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO:

Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

	Approved for the filled in case in the second and
	U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are	e required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449/PTO			Complete if Known			
				Application Number	10/580,011	
INF	ORMATION	N DIS	CLOSURE	Filing Date		
STATEMENT BY APPLICANT		First Named Inventor	Tim Fat Tam			
				Art Unit		
	(Use as many sh	eets as n	ecessary)	Examiner Name		·
Sheet	3	of	3	Attorney Docket Number	PT2116001	

		NON PATENT LITERATURE DOCUMENTS	
Initials* No.¹ the item (book, ma		Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T²
		RAKBA et al., Iron Mobilisation and Cellular Protection by a New Synthetic Chelator O-Trensox, Biochemical Pharmacology, 1998, 55(11), pp. 1797-1806	
		SINGH et al., Urinary Metabolic Profiles in Human and Rat of 1,2-Dimethyl- and 1,2-Diethyl-Substituted, Drug Metabolism and Disposition, 1992, Vol. 20, No. 2, pp. 256-261	
		TAM et al., Iron Chelator Research: Past, Present, and Future, Current Medicinal Chemistry, June 2003, Vol. 10, No. 12, pp. 983-995	
	-	VAN ASBECK et al., Anti-HIV effect of iron chelators: different mechanisms involved, Journal of Clinical Virology, February 2001, Vol. 20, No. 3, pp. 141-147	
Br	/	VOEST et al., Iron-Chelating Agents in Non-Iron Overload Conditions, Annals of Internal Medicine, 1994, Vol. 120, No. 6, pp. 490-499	
7			

Examiner Signature	Date Considered	2/4/	98
*EXAMINER: Initial of peregree considered, whether or not citation is in conformance with MPEP 609	Draw line through c	itation if not i	n conformance and not

*EXAMINER: Initially prepared considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The Information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.